First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([¹⁶¹Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

Eur J Nucl Med Mol Imaging. 2024 Mar 7. doi: 10.1007/s00259-024-06641-w. Online ahead of print.

Julia Fricke¹, Frida Westerbergh², Lisa McDougall¹, Chiara Favaretto^{1

3}, Emanuel Christ^{4

5}, Guillaume P Nicolas^{1

4}, Susanne Geistlich³, Francesca Borgna³, Melpomeni Fani⁶, Peter Bernhardt^{2

7}, Nicholas P van der Meulen^{3

8}, Cristina Müller^{3

9}, Roger Schibli^{3

9}, Damian Wild^{10

11}

¹ Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
² Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
³ Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland.
⁴ ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland.
⁵ Division of Endocrinology, University Hospital Basel, Basel, Switzerland.
⁶ Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland.
⁷ Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden.
⁸ Laboratory of Radiochemistry, Paul Scherrer Institute (PSI), Villigen, Switzerland.
⁹ Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
¹⁰ Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland. damian.wild@usb.ch.
¹¹ ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland. damian.wild@usb.ch.

No abstract available